Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12–17 year-old adolescents

Pio Lopez, Lulu Bravo, Erik Buntinx, Charissa Borja-Tabora, Hector Velasquez, Edith Johana Rodriguez, Camilo A. Rodriquez, Josefina Carlos, May Emmeline B. Montellano, Edison R. Alberto, Milagros Salvani-Bautista, Yung Huang, Branda Hu, Ping Li, Htay Htay Han, Carmen Baccarini, Igor Smolenov
doi: https://doi.org/10.1101/2023.02.22.23286317

Data Availability

The datasets, including the redacted study protocol, redacted statistical analysis plan, and individual participants data supporting the results reported in this article, will be available three months from initial request, to researchers who provide a methodologically sound proposal. The data will be provided after its de-identification, in compliance with applicable privacy laws, data protection and requirements for consent and anonymization.

Back to top
Posted February 26, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12–17 year-old adolescents
Pio Lopez, Lulu Bravo, Erik Buntinx, Charissa Borja-Tabora, Hector Velasquez, Edith Johana Rodriguez, Camilo A. Rodriquez, Josefina Carlos, May Emmeline B. Montellano, Edison R. Alberto, Milagros Salvani-Bautista, Yung Huang, Branda Hu, Ping Li, Htay Htay Han, Carmen Baccarini, Igor Smolenov
medRxiv 2023.02.22.23286317; doi: https://doi.org/10.1101/2023.02.22.23286317
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area